Abivax (ABVX) had its "buy" rating reaffirmed by BTIG Research. They now have a $150.00 price target on the stock.
Abivax (NASDAQ:ABVX) is now covered by analysts at Wedbush. They set an "underperform" rating on the stock.
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Better Long-Term Buy: This Emerging Player or the Industry Leader? [Yahoo! Finance]
Prediction: This Healthcare Stock Could Soar by 72% in 2026 [Yahoo! Finance]